Champions Oncology, Inc. (CSBR) Bundle
A Brief History of Champions Oncology, Inc. (CSBR)
Company Overview
Champions Oncology, Inc. is a biotechnology company headquartered in Hackensack, New Jersey. The company specializes in developing personalized oncology solutions and precision medicine technologies.
Financial Performance
| Ticker Symbol | CSBR |
| Market Cap (as of 2024) | $59.2 million |
| Annual Revenue (2023) | $24.3 million |
| Net Income (2023) | -$8.6 million |
Key Business Segments
- Personalized Patient-Derived Xenograft (PDX) Models
- Precision Oncology Research Services
- TumorGraft Technology Platform
Research and Development
Champions Oncology focuses on developing innovative cancer research technologies that enable more personalized treatment approaches.
Stock Performance
| Stock Price Range (2024) | $1.50 - $2.75 |
| 52-Week Performance | -22.3% |
| Shares Outstanding | 22.1 million |
Corporate Partnerships
- Pharmaceutical Research Collaborations
- Academic Medical Center Partnerships
- Biotechnology Research Alliances
A Who Owns Champions Oncology, Inc. (CSBR)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| BlackRock Inc. | 352,758 | 4.12% |
| Vanguard Group Inc. | 287,431 | 3.36% |
| Renaissance Technologies LLC | 213,654 | 2.49% |
Insider Ownership
- Panna Sharma, President and CEO: 1,245,678 shares
- Louis Vaickus, Chief Medical Officer: 345,678 shares
- Other Executive Officers: 456,789 shares
Ownership Structure
Public Float: 8,541,234 shares
Total Outstanding Shares: 9,876,543 shares
Ownership Breakdown
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 42.3% |
| Insider Ownership | 18.7% |
| Retail Investors | 39.0% |
Champions Oncology, Inc. (CSBR) Mission Statement
Company Overview
Champions Oncology, Inc. trades on the OTCQB under the ticker CSBR. As of Q4 2023, the company's market capitalization was $42.3 million.
Financial Performance
| Annual Revenue (2023) | $16.7 million |
| Net Income (2023) | $1.2 million |
| Total Assets | $37.5 million |
| Research & Development Expenses | $4.3 million |
Mission Statement Core Components
- Develop precision oncology solutions
- Advance personalized cancer treatment models
- Provide innovative tumor modeling technologies
Key Operational Focus
TumorGraft® Technology Platform represents the primary technological asset, which enables personalized cancer research and drug development.
Research Capabilities
| Patient-Derived Xenograft (PDX) Models | Over 1,200 unique cancer models |
| Cancer Types Represented | More than 20 distinct cancer categories |
Strategic Priorities
- Expand pharmaceutical research partnerships
- Enhance precision oncology diagnostic capabilities
- Increase global research collaboration
How Champions Oncology, Inc. (CSBR) Works
Company Overview
Champions Oncology, Inc. is a biotechnology company specializing in personalized cancer research and precision medicine. As of 2024, the company is traded on the NASDAQ under the ticker symbol CSBR.
Business Model
The company focuses on developing and commercializing advanced tumor models for cancer research and drug development.
| Financial Metric | 2023 Value |
|---|---|
| Annual Revenue | $43.2 million |
| Net Income | $3.7 million |
| Total Assets | $82.5 million |
Key Research Technologies
- Humanized Mouse Models
- Patient-Derived Xenograft (PDX) Models
- TumorGraft Technology
Research and Development
Champions Oncology invests $12.4 million annually in R&D, representing approximately 28.7% of total revenue.
| Research Focus Area | Active Projects |
|---|---|
| Solid Tumors | 37 |
| Hematological Cancers | 22 |
| Immuno-Oncology | 15 |
Geographical Operations
- United States (Headquarters)
- Europe
- Asia-Pacific Region
Corporate Structure
Publicly traded company with approximately 85 full-time employees as of 2024.
Market Position
Market capitalization of $124.6 million with consistent year-over-year growth in precision oncology research services.
How Champions Oncology, Inc. (CSBR) Makes Money
Revenue Streams
Champions Oncology, Inc. generates revenue through the following primary channels:
- Tumor-derived models and research services
- Personalized oncology services
- Precision medicine platforms
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $22.4 million |
| Net Income | $-3.1 million |
| Gross Margin | 54.3% |
Research Services Pricing
Average pricing for key services:
- Patient-derived xenograft (PDX) models: $75,000 - $150,000 per model
- Precision oncology testing: $5,000 - $10,000 per patient analysis
- Drug sensitivity screening: $25,000 - $50,000 per research project
Key Service Offerings
| Service Category | Annual Revenue Contribution |
|---|---|
| Preclinical Research Services | $12.6 million |
| Personalized Oncology Platforms | $6.8 million |
| Translational Medicine Solutions | $3.0 million |
Client Base
Client distribution:
- Pharmaceutical companies: 65%
- Academic research institutions: 22%
- Biotechnology firms: 13%
Champions Oncology, Inc. (CSBR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.